The story of HCA Healthcare's second quarter is not the topline. Revenues of $20.2 billion rose 8.7% on a consolidated basis. The same-facility comparison rose 9.3%, but a striking share of that headline growth came from a single regulatory event: the Centers for Medicare & Medicaid Services approved Florida's directed payment program during the quarter. That approval handed HCA $1.372 billion of incremental revenue. It covered the period from October 2024 through June 2026. Strip the one-time catch-up out and the underlying revenue print is more pedestrian, which is the first thing investors should internalize about the headline beat. The same quarter's Medicaid revenue mix jumped from 7.7% to 13.8% almost entirely because of that one Florida recognition, the cleanest illustration of the gap between reported growth and underlying growth that investors should carry into the rest of the report.
The demand backdrop is bifurcating. Same-facility equivalent admissions grew 2.7%. Emergency department visits grew 3.6%, both encouraging. Inpatient surgeries declined 2.3%. Outpatient surgeries fell several percentage points. Same-facility uninsured admissions jumped 23.4% as the enhanced premium tax credits that subsidized Exchange coverage expired at the end of 2025. The uninsured share of total admissions has moved up by roughly two percentage points year over year. Most of those uninsured patients are concentrated in Texas and Florida. The associated uncompensated-care cost, an estimated $1.445 billion in the second quarter, is the direct financial consequence of every additional uninsured admission. It explains why the quarter's net-income growth lagged revenue growth by several percentage points. The mix that worked for a decade is now meeting a reimbursement regime that punishes hospitals with uninsured bad debt when Exchange subsidies lapse. That single observation, more than any other figure in the filing, is what should drive investor posture into the second half of 2026.
For investors, this leaves a recognizable HCA story on a different footing. Operating discipline is intact: salaries and benefits as a percent of revenues improved from 43.7% to 41.0%. Net income attributable to HCA reached $1.699 billion, or $7.62 per diluted share. Capital intensity has stepped up. Management is guiding to roughly $5 billion of capital expenditures this year. Debt sits at $49.7 billion. The market is paying roughly $413 for a share that earned $7.62 last quarter. That share trades at a low-teens forward earnings multiple. The diluted share count has fallen by nearly twenty million a year ago. The central question is whether the Medicaid and uninsured pressure is a one-quarter policy hangover or the early innings of a structural shift in who shows up at HCA's doors.